ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,306.04
0.02%
US Tech 100
18,387.60
0.38%
Dow Jones
38,852.86
-0.55%
Brent Oil
84.155
-0.20%
Bitcoin
68,797.90
0.74%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. AN2 Therapeutics Inc (ANTX) Quote

AN2 Therapeutics Inc

AN2 Therapeutics Inc (ANTX)

NASDAQ
2.12
0.10
(4.95%)
Closed May 28 4:00PM
Delayed by 15 minutes
2.08
-0.04
(-1.89%)
After Hours: 6:14PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
2.08
Bid
2.02
Ask
2.31
Volume
119,517
2.02 Day's Range 2.13
1.92 52 Week Range 22.22
Market Cap
62.754M
Previous Close
2.02
Open
2.05
Last Trade
740
@
2.08
(formt)
Last Trade Time
Financial Volume
$ 249,696
VWAP
2.0892
Average Volume (3m)
288,235
Shares Outstanding
29,741,445
Dividend Yield
-
PE Ratio
-0.97
Earnings Per Share (EPS)
-2.18
Revenue
-
Net Profit
-64.73M

About AN2 Therapeutics Inc

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NT... AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.an2therapeutics.com
Headquarters
Dover, Delaware, USA
Founded
1970
AN2 Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ANTX. The last closing price for AN2 Therapeutics was $2.02. Over the last year, AN2 Therapeutics shares have traded in a share price range of $ 1.92 to $ 22.22.

AN2 Therapeutics currently has 29,741,445 shares outstanding. The market capitalization of AN2 Therapeutics is $62.75 million. AN2 Therapeutics has a price to earnings ratio (PE ratio) of -0.97.

ANTX Latest News

More News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 14 2024
Edgar (US Regulatory)

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

May 14 2024
Edgar (US Regulatory)

AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights

Plan to report Phase 2 topline results in August 2024 from ongoing Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) Phase 3 continues for 97 patients...

May 14 2024
Business Wire

AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during...

March 28 2024
Business Wire

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

February 13 2024
Edgar (US Regulatory)

Form 8-K - Current report

February 12 2024
Edgar (US Regulatory)

AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease

-Enrolled patients allowed to continue on study- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious...

February 12 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.16-7.142857142862.242.251.921352702.05922261CS
4-0.31-12.97071129712.392.671.921079212.31245857CS
12-0.78-27.27272727272.863.881.922882352.94767102CS
26-14.12-87.160493827216.222.221.923049535.85017859CS
52-3.29-61.26629422725.3722.221.921929376.9285941CS
156-14.77-87.655786350116.8523.581.921161108.22757333CS
260-14.77-87.655786350116.8523.581.921161108.22757333CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
STSSSharps Technology Inc
$ 0.5289
(146.80%)
302.07M
AWINAERWINS Technologies Inc
$ 8.99
(139.10%)
5.41M
INSMInsmed Inc
$ 48.107
(118.67%)
33.41M
GVVisionary Holdings Inc
$ 0.38
(90.00%)
10.33M
SOBRSOBR Safe Inc
$ 0.41
(82.22%)
130.83M
APDNApplied DNA Sciences Inc
$ 0.580601
(-70.82%)
9.45M
LUCYInnovative Eyewear Inc
$ 0.40
(-59.31%)
84.98M
MRAIMarpai Inc
$ 0.90
(-53.61%)
803.83k
TOIIWOncology Institute Inc
$ 0.021
(-52.60%)
293.22k
SHOTWSafety Shot Inc
$ 0.21
(-36.07%)
24.26k
PEGYPineapple Energy Inc
$ 0.2595
(45.70%)
676.58M
GWAVGreenwave Technology Solutions Inc
$ 0.0782
(-7.89%)
306.52M
STSSSharps Technology Inc
$ 0.5289
(146.80%)
302.07M
CRKNCrown Electrokinetics Corporation
$ 0.1073
(6.24%)
232.53M
OBLGOblong Inc
$ 0.21
(19.32%)
146.15M

ANTX Discussion

View Posts
GO4AWILDRIDE GO4AWILDRIDE 2 months ago
FROM 3/28 NEWS:

Cash, cash equivalents, and investments of $134.5 million at December 31, 2023

GO4AWILDRIDE
👍️0
GO4AWILDRIDE GO4AWILDRIDE 2 months ago
THE FOLLOWING FROM THE 3/28 NEWS:

“AN2’s cash position remains strong as we advance our innovative boron-based pipeline. Following the recent meeting of the independent Data Safety Monitoring Board, we continue to believe in the potential of epetraborole to become an important component of the backbone therapy for NTM lung disease,” said Eric Easom, Co-Founder, President and Chief Executive Officer. “Patients enrolled in the epetraborole Phase 2/3 trial in treatment refractory lung disease caused by MAC continue to be dosed while new enrollment in the Phase 3 part of the trial remains paused. Patients in the Phase 2 trial have reached the six-month mark, and we plan to report topline results this summer. Analysis of the baseline patient demographics from the trial show a highly complex and refractory patient population, which we plan to discuss with the FDA in the coming months.”

GO4AWILDRIDE
👍️0
GO4AWILDRIDE GO4AWILDRIDE 2 months ago
Monksdream

Did you read the 3/28 news from the compay?

Seems like the market is looking to chase the price up.

GLTU

GO4AWILDRIDE
👍️0
GO4AWILDRIDE GO4AWILDRIDE 2 months ago
Monksdream

Seems like a nice rebound is starting to occur.

GLTU

GO4AWILDRIDE
👍️0
Monksdream Monksdream 3 months ago
ANTX new 52 week low
👍️0
Monksdream Monksdream 3 months ago
ANTX new 52 week low
👍️0
Monksdream Monksdream 3 months ago
ANTX new 52 week low
👍️0

Your Recent History

NASDAQ
ANTX
AN2 Therapeutics
BIT
UB7RVK
Unicredit Bank
BIT
P1DD61
BNP Paribas Issuance
BIT
UID169
Unicredit Bank
ASX
SFYJOZ
EU
U166S
U166S
BIT
P1YZJ9
NLBNPIT1YZJ9 20991231 43...
NASDAQ
ETSY
Etsy
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved